For Research Use Only
Not for Use in Diagnostic Procedures
For in vitro use only

| Description: | Factor XIla-beta (Human) |
| ---: | :--- |
| Format: | Lyophilized in 4 mM sodium acetate- $\mathrm{HCl} / 0.15 \mathrm{M} \mathrm{NaCl} / \mathrm{pH} 5.2$ |
| Host: | Human |
| Storage: | Store between +2 and $+8^{\circ} \mathrm{C}$ <br> After reconstitution aliquot and freeze at $\leq-60^{\circ} \mathrm{C}$ <br> Reconstitution: We recommend hydrating the protein with sterile water to the original volume |
| Volume: | 1 vial containing 0.058 mL |
| Total Protein: | 0.10 mg |
| Concentration: | $1.71 \mathrm{mg} / \mathrm{mL}$ before lyophilisation by Absorbance; Extinction Coefficient $\mathrm{E}^{1 \%}{ }_{280}=14.1$ |
| Molecular weight: | 30,000 daltons |

Coagulation Factor XII (FXII) is a 76 kDa protein synthesized in the liver. Cleavage by kallikrein after residue Arg353 produces the enzyme $\alpha$ FXIla consisting of a 28 kDa light chain containing the protease domain and a 52 kDa heavy chain containing the anionic surface-binding domain.

Further cleavage of $\alpha$ FXIIa by trypsin produces the 30 kDa fragment $\beta$ FXIIa.
The activity of FXIIa is regulated by C1-Inhibitor with minor contributions by $\alpha 2$-antiplasmin, $\alpha 2$-macroglobulin and antithrombin. The normal FXII protease zymogen concentration in human plasma is about $30 \mu \mathrm{~g} / \mathrm{mL}(400 \mathrm{nM})$.

The human Factor XIla was activated from homogeneous human Factor XII using Dextran Sulfate. This Dextran Sulfate was removed after activation. Complete activation with was observed on SDS-Page.

The above protein was purified from Human plasma that was tested and found negative by FDA accepted methods for Anti-HIV 1/2, Anti-HTLV I \& II, HBsAg, Anti-HCV, Syphilis, HBC Ab, HIV-1 p24 Ag or HIV-1 RNA, HCV RNA and HBV RNA. Donors are screened for CJD (Creutzfeld-Jakob Disease).

